Cameco's India Uranium Deal Bolsters Contract Book But Fails to Ease Valuation or Execution Risks

What happened

Cameco has inked a $1.9 billion long-term uranium supply pact with India, committing 22 million pounds through 2036, as nuclear power expansion gains momentum globally. The DeepValue master report emphasizes that Cameco's investment case revolves around term contracting proof, with U.S. utilities reporting 184 million pounds of unfilled requirements through 2034. This deal adds to Cameco's ~230 million pounds committed under long-term contracts, aligning with the replacement-rate contracting narrative critical to earnings growth. However, the stock trades at a rich 119x P/E, already discounting sustained contracting and Westinghouse cash flows, while key risks like production delays and EIA data confirmation loom. Thus, while the India contract is a positive operational step, it does not resolve the valuation overhang or execution challenges highlighted in the report.

Implication

The India supply deal enhances Cameco's revenue visibility and supports the global nuclear demand story, potentially boosting investor sentiment. It contributes to filling the uncovered utility requirements cited in the DeepValue report, though it does not directly address U.S.-specific EIA data needed for thesis confirmation. With Cameco guiding 2026 deliveries of 29-32 million pounds against production of 19.5-21.5 million pounds, procurement and execution risks persist, as seen in past McArthur River delays. At 119x P/E, the stock offers limited margin of safety, and positive price action may be muted without broader term-market acceleration. Therefore, maintaining a 'WAIT' stance is advisable until the June 2026 EIA update provides clearer evidence of contracting cadence.

Thesis delta

The India deal marginally strengthens the term contracting component of the thesis by adding a long-term commitment, but it does not alter the core valuation or risk concerns. Key uncertainties around U.S. utility contracting proof via EIA data and operational execution remain unchanged, sustaining the 'WAIT' rating. Investors should still prioritize the upcoming EIA report and production updates as primary catalysts for any rating shift.